Kaladhar B Reddy
Overview
Explore the profile of Kaladhar B Reddy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
866
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Venkatesh J, Rishi A, Reddy K
Genes Cancer
. 2021 Jan;
11(3-4):95-105.
PMID: 33488948
Previous studies from our group and others have shown that current drug treatment(s) strategies eliminate bulk of tumor cells (non-CSCs) but it had a minimal effect on cancer stem cells...
2.
Reddy K
Genes (Basel)
. 2020 Nov;
11(11).
PMID: 33233552
Cancer stem cells (CSCs) are a class of pluripotent cells that have been observed in most types of cancers. Evolving evidence suggests that CSCs, has the ability to self-renew and...
3.
Yin S, Cheryan V, Xu L, Rishi A, Reddy K
PLoS One
. 2017 Aug;
12(8):e0183578.
PMID: 28817737
Women with triple negative breast cancer (TNBC) have poor prognosis compared to other breast cancer subtypes. There were several reports indicating racial disparity in breast cancer outcomes between African American...
4.
Muthu M, Somagoni J, Cheriyan V, Munie S, Levi E, Ashour A, et al.
J Biomed Nanotechnol
. 2015 Oct;
11(9):1608-27.
PMID: 26485930
The triple negative breast cancer (TNBCs) and non-small cell lung cancers (NSCLCs) often acquire mutations that contribute to failure of drugs in clinic and poor prognosis, thus presenting an urgent...
5.
Ahmad A, Ginnebaugh K, Yin S, Bollig-Fischer A, Reddy K, Sarkar F
BMC Cancer
. 2015 Jul;
15:540.
PMID: 26206152
Background: For breast cancer patients diagnosed with estrogen receptor (ER)-positive tumors, treatment with tamoxifen is the gold standard. A significant number of patients, however, develop resistance to tamoxifen, and management...
6.
Reddy K
Cancer Cell Int
. 2015 May;
15:38.
PMID: 25960691
In recent years, there has been a tremendous and growing interest among researchers to investigate the role of mircoRNA (miRNA) in normal cellular as well as in disease processes. miRNAs...
7.
Yin S, Rishi A, Reddy K
Oncol Rep
. 2015 Jan;
33(3):1475-80.
PMID: 25592673
Breast cancer patients who are positive for estrogen receptor (ER) are usually treated with anti-estrogen drugs, such as tamoxifen (Tam). However, a great majority of such patients eventually develop resistance...
8.
Yin S, Xu L, Bonfil R, Banerjee S, Sarkar F, Sethi S, et al.
Mol Cancer Ther
. 2013 Mar;
12(4):491-8.
PMID: 23445611
Triple-negative breast cancer (TNBC) studies have shown that neoadjuvant chemotherapy before surgery was effective in the minority of women, whereas the majority who had residual tumor had a relatively poor...
9.
Yin S, Xu L, Bandyopadhyay S, Sethi S, Reddy K
Int J Oncol
. 2011 Jun;
39(4):891-8.
PMID: 21687939
Triple negative breast cancer (TNBC) has increased recurrence and poor survival, despite a high response rate to neoadjuvant chemotherapy. The aim of this study was to determine whether current drug...
10.
Xu L, Yin S, Banerjee S, Sarkar F, Reddy K
Mol Cancer Ther
. 2011 Jan;
10(3):550-7.
PMID: 21252285
Women with triple-negative breast cancer (TNBC) have a worse prognosis compared with other breast cancer subtypes. Hormonal or Herceptin-based therapies were found to be ineffective because of the loss of...